Expression Data from DLBCL Cell Line U2932 (Parental, CDC-Treated, and CDC-Resistant) and 8 DLBCL Patient Samples (5 High CDC-Sensitive, 3 Low CDC-Sensitive)

Complement-dependent cytotoxicity (CDC) is an important effector function of various therapeutic antibodies. Cancer cells often develop resistance to CDC, mainly due to external factors. In this study, using models of diffuse large B-cell lymphoma (DLBCL), we compared gene expression levels between the parental U2932 and CDC-resistant U2932 DLBCL cell lines, as well as gene expression differences between highly CDC-sensitive and low CDC-sensitive DLBCL patient samples. Hereby, we aimed to identify intrinsic regulators of CDC. Overall design: Gene expression levels were compared between the parental U2932 DLBCL cell line (U2932-WT), the U2932-Treated cells (U2932-Tr) that were exposed once to antibody-induced complement activation, and the U2932-Resistant (U2932-R) cells that were CDC-resistant by repeated exposure to antibody-induced complement. Gene expression levels were also compared between high CDC-sensitive (n=5) and low CDC-sensitive (n=3) cancer B-cells isolated and sorted (CD19+CD3-) from lymph nodes of DLBCL patients.